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ABSTRACT
Introduction: Longer medication persistence in
type 2 diabetes (T2D) is associated with
improved glycaemic control. It is not clear
which oral therapies have the best persistence.
The objective of this study was to compare
medication persistence across different oral
therapies in people with T2D.
Methods: We performed a retrospective cohort
analysis using a primary-care-based population,
the Royal College of General Practitioners
Research and Surveillance Centre cohort. We
identified new prescriptions for oral diabetes
medication in people with type 2 diabetes
between January 1, 2004 and July 31, 2015. We
compared median persistence across each class.
We also compared non-persistence (defined as a
prescription gap of C 90 days) between classes,
adjusting for confounders, using Cox regres-
sion. Confounders included: age, gender,
ethnicity, socioeconomic status, alcohol use,
smoking status, glycaemic control, diabetes
duration, diabetes complications, comorbidi-
ties, and number of previous and concurrent
diabetes medications.
Results: We identified 60,327 adults with T2D.
The majority 42,810 (70.9%) of those had one
or more oral medications prescribed; we mea-
sured persistence in those patients (who were
prescribed 55,728 oral medications in total).
Metformin had the longest median persistence
(3.04 years; 95% CI 2.94–3.12). The adjusted
hazard ratios for non-persistence compared
with metformin were: sulfonylureas HR 1.20
(1.16–1.24), DPP-4 inhibitors HR 1.43
(1.38–1.49), thiazolidinediones HR 1.71 (95%
CI 1.64–1.77), SGLT2 inhibitors HR 1.04
(0.93–1.17), meglitinides HR 2.25 (1.97–2.58),
and alpha-glucosidase inhibitors HR 2.45
(1.98–3.02). The analysis of SGLT2 inhibitors
was limited by the short duration of follow-up
for this new class. Other factors associated with
reduced medication persistence were female
gender, younger age, and non-white ethnicity.
Conclusions: Persistence is strongly influenced
by medication class and should be considered
when initiating treatments.
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INTRODUCTION
Management of chronic disease often requires
one or more medications to be taken over the
full or partial life span of the disease. In this
respect, treatment adherence and persistence
should be given particular attention as failure to
comply may result in earlier deterioration of the
condition and sub-optimal outcomes [1]. In
developed countries, adherence to therapies
among patients suffering from chronic diseases
averages 50%, and it is thought to be even less
in developing countries due to reduced access
to, and the limitations of, healthcare resources
[1, 2]. With an aging population globally, the
burden of people suffering from chronic dis-
eases is expected to increase, resulting in poor
health outcomes for individual patients and
increases in healthcare costs leading to bud-
getary challenges for many governments [3, 4].
Poor adherence is a well-recognised problem
among people with type 2 diabetes [5–8], with a
high proportion of people failing to take their
medication as prescribed [9, 10]. This can result
in worse clinical outcomes, including poor gly-
caemic control [11–16], increased hospital
admissions [17–20], increased healthcare costs
[21–27], higher risk of cardiovascular events
[28, 29], increased mortality [15, 18, 30–32],
reduced health-related quality of life, and
increased burden of diabetes. A meta-analysis by
Krass et al. [33] reported a prevalence of adher-
ence ranging from 38.5% to 93.1%, with the
majority of studies (21/27) reporting good
adherence in under 80% of people.
Several factors contribute to poor adherence:
the World Health Organization (WHO) has
identified five main categories [1]; patient-re-
lated (e.g. age), socioeconomic (e.g. medication
costs), condition-related (e.g. presence of com-
plications), health-system-related (e.g. level of
continuity of care), and therapy-related (e.g.
adverse effects) [12, 14]. There are two discrete
patterns of medication non-use, which may be
classed as missed medication doses (described
by the terms adherence, compliance, or con-
cordance) and duration of use before discon-
tinuation (persistence) [34]. Accurate
assessment of adherence and persistence
behaviour, along with accurate data capture and
analysis, are necessary for effective and efficient
treatment planning, and for ensuring that
changes in health outcomes can be attributed to
the recommended regimen. Estimated level of
persistence (ELPT) (the percentage of individu-
als remaining on therapy at a given time), the
proportion of days covered (PDC) method (the
number of days with the drug available divided
by the number of days in the specified time
interval), or the medication possession ratio
(MPR) method (total days supply for all pre-
scriptions filled within a period divided by the
number of days in the specified time interval)
are often used along with the number of days to
discontinuation and number of prescription
refills over a period of time [35, 36].
The aim of the study reported in the present
paper was to compare persistence with various
oral medications in type 2 diabetic patients, and
to identify factors that influence persistence in a
real-world setting using a primary-care-based
population and with non-persistence defined as
a prescription gap of C 90 days.
METHODS
We performed a retrospective cohort analysis in
adults with type 2 diabetes to compare medi-
cation persistence across all noninsulin medi-
cation classes used in the treatment of
hyperglycaemia. The cohort was identified from
the Royal College of General Practitioners
Research and Surveillance Centre (RCGP-RSC)
database. This comprises primary care data from
a sentinel network of general practices dis-
tributed across England. At the time of analysis,
the database contained primary care records
collected from 1,238,909 people registered with
128 practices. The database includes all recor-
ded clinical codes with associated values and
dates for the population from January 1, 2004 to
January 1, 2015. These clinical codes are recor-
ded using the Read coding system and include
diagnosis codes, medication codes, investiga-
tion codes, and process of care codes. This large
primary care database has been demonstrated to
be representative of the UK population,
Diabetes Ther
although less socioeconomically deprived peo-
ple are slightly overrepresented [37].
We used a two-step process to identify peo-
ple with type 2 diabetes, which we have repor-
ted in full previously [38]. In brief, the first step
identified all people with diabetes (of any type),
defined as those who had a diagnostic code
(diagnosis of diabetes), clinical investigations
(two or more fasted, random, or glucose toler-
ance test values or HbA1c measurements con-
sistent with diagnosis), or medication use (two
or more prescriptions for oral diabetes medica-
tions, excluding metformin or injectable thera-
pies). These people were then categorised by
diabetes type using a clinically-based seven-step
algorithm. This method was chosen to min-
imise the impact of misdiagnosis, misclassifica-
tion and miscoding, which has previously been
identified in people with diabetes [39, 40]. All
adults (age C 18 years) with identified type 2
diabetes were included for analysis.
Within the adult type 2 diabetes population,
we identified all new medication prescriptions
for metformin, sulfonylureas, dipeptidyl pepti-
dase-4 (DPP-4) inhibitors, thiazolidinediones,
sodium-glucose cotransporter 2 (SGLT2) inhi-
bitors, meglitinides, and alpha-glucosidase
inhibitors between January 1, 2005 and
December 31, 2015. We did not examine per-
sistence with fixed-dose combination therapies.
To be included as a new prescription, we
required a minimum of 6 months of registration
prior to the first prescription occurrence for the
medication of interest. People with only one
prescription for the medication of interest were
excluded from the analysis. We followed per-
sistence for each newly prescribed medication.
Non-persistence was defined as a gap in pre-
scriptions of C 90 days. The duration of persis-
tence was defined as the time interval between
the first prescription and the last identified
prescription consistent with persistence. Only
people currently registered with the primary
care practice from which their data were
extracted were included. People who had died
or were unregistered at the time of data collec-
tion (January 1, 2016) were not included. People
who had a final prescription for the medication
within 90 days of the end of follow-up were
categorised as having censored persistence and
included for analysis. All available data were
used to follow-up people with type 2 diabetes
either from registration with their current pri-
mary care practice, the earliest available records
(January 2004), or the diagnosis of type 2 dia-
betes (whichever was latest).
People were considered to be non-persistent
if they switched medication within a class; for
example, a change from sitagliptin to linaglip-
tin was considered to be non-persistence with
sitagliptin—two persistence events were then
included for analysis (one with sitagliptin and
one with linagliptin). People who switched
medication preparation (for example met-
formin standard release to metformin modified
release) were considered to be persistent. We
only consider primary persistence (i.e. persis-
tence from the first recorded prescription of
each medication).
Statistical Methods
For each medication class included, we report
the proportion of people remaining persistent
at 6 months, 1 year, 2 years, and 5 years, with
95% confidence intervals (95% CI). We also
report the crude median persistence duration
with each class with 95% confidence intervals.
We used Cox regression analysis to identify
the independent influences of multiple vari-
ables on medication persistence. Factors inclu-
ded in the regression analysis comprised age,
gender, ethnicity, socioeconomic status (mea-
sured using the Index of Multiple Deprivation;
IMD score), smoking status, alcohol intake,
duration of diabetes, glycaemic control, pres-
ence of complications, presence of comorbidi-
ties, number of concurrent diabetes
medications, number of previous non-persistent
diabetes medications, and medication class.
Ethnicity was defined using the Office of
National Statistics (ONS) official UK ethnicity
categories: this defines five major ethnic cate-
gories: white, mixed/multiple ethnic groups,
Asian (including Indian, Pakistani, Bangladeshi,
and Chinese people), black (including African
and Caribbean people), and other (including
Arab and other minority groups not classified
elsewhere) [41].
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Socioeconomic status was derived using the
nationally recognised measure IMD, based on
patient postcode. Smoking status and alcohol
use were defined using the most recently
recorded measure. Duration of diabetes was
defined as the time between the first recorded
indicator of diabetes (diagnostic code, blood
glucose measure consistent with diabetes, or
medication) in the record and the time of ini-
tiation of the medication of interest. In the
population characteristics table, the duration of
diabetes is defined as the time between the first
indicator of diabetes and the date of data
extraction (January 1, 2016). Body mass index
(BMI) and blood pressure were defined using the
value most recently recorded prior to the initi-
ation of the medication of interest. The pres-
ence of diabetes complication and
comorbidities was determined by the presence
of diagnosis codes or other codes specific for the
diagnosis (e.g. read code ‘‘6A9..’’ ‘‘Atrial fibrilla-
tion annual review’’ as a code to identify the
presence of atrial fibrillation). The diabetes
complications identified comprised amputa-
tion, peripheral neuropathy, retinopathy, and
peripheral vascular disease. The comorbidities
identified comprised hypertension, atrial fibril-
lation, angina, stroke, myocardial infarction,
congestive cardiac failure, transient ischaemic
attack (a history of), coronary artery disease,
chronic kidney disease (CKD 3–5), renal
replacement therapy (dialysis or transplant),
dementia, depression, rheumatoid arthritis, and
chronic liver disease (any cause). Chronic kid-
ney disease was identified using estimated
glomerular filtration rate (eGFR) measurements
and diagnosis codes. Counts of previous and
concurrent diabetes medications included
fixed-dose combination therapies, which were
counted as one additional medication.
All variables included were categorical to
account for nonlinear relationships with the
outcome measure. Model selection was per-
formed by backwards stepwise elimination of
nonsignificant variables (p[0.05) to minimise
the Akaike information criterion (AIC). The
outcome event was defined as non-persistence
(no repeat prescription collected within 90 days
of the previous prescription), with hazard ratios
(HR) for non-persistence reported with 95%
confidence intervals. Each new medication
started was considered a persistence event, so
several persistence events were analysed for
patients initiated on several medications. We
report R2 as a measure of model performance.
We used the statistical package R version 3.3.1
for the statistical analysis.
Compliance with Ethics Guidelines
All data used were anonymised at the point of
data extraction. No clinically identifiable infor-
mation was available to researchers. The study
was been tested against the Health Research
Authority (HRA)/Medical Research Council
(MRC) ‘‘is this research’’ tool (http://www.hra-
decisiontools.org.uk/research/), and was con-
sidered to be an audit of current practice when
compared to the best available evidence. The
study therefore did not require specific ethical
approval. Approval for this work was granted by
the RCGP RSC study approval committee prior
to initiation.
RESULTS
From a total RCGP RSC cohort of 1,238,909
people from 128 primary care practices, 64,909
(5.2%) people were identified as having dia-
betes. Of these 60,327 (92.9%) were categorised
as type 2 diabetes; a crude prevalence of 6.05%
type 2 diabetes in adults. The age-gender direct
standardised prevalence for type 2 diabetes in
the cohort was 6.25% (95% CI 6.20–6.30%),
comparable to the 2011 UK census. In the type 2
diabetes population, the mean age was 66.1 (SD
13.8) years, and 26,792 (41.3%) were female
(Table 1).
The median duration of follow-up was 6.6
(IQR 3.17–10.9) years. During the follow-up
period, the majority 42,810 (70.9%) of the
people had one or more oral medications pre-
scribed. Metformin was the most commonly
prescribed medication, followed by sulfony-
lureas (Table 2).
We measured persistence with 55,728 oral
medications (Table 2). Non-persistence occur-
red with 38,169 (68.5%) of those during follow-
up. The remaining 17,559 medications had
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ongoing persistence at the end of follow-up.
The median persistence duration overall was
2.25 (95% CI 2.20–2.30) years. Metformin had
the longest crude persistence and alpha-
glucosidase inhibitors had the shortest, with
persistence trends consistent from 6 months to
5 years (Table 3).
Table 1 The characteristics of all adults with identiﬁed type 2 diabetes included for analysis (n = 60,327)
Characteristic n (%) or mean (SD) Characteristic n (%) or mean (SD)
Age recorded 60,327 (100.0) HbA1c measured 57,159 (94.7)
Age (years) 66.1 (13.8) HbA1c (mmol/mol)b 61.9 (22.4)
Gender recorded 60,327 (100.0) BMI measured 59,043 (97.9)
Female 26,792 (44.4) BMI (kg m-2) 30.7 (6.4)
Ethnicity recorded 51,747 (85.8) Blood pressure measured 60,106
White 42,284 (70.1) SBP (mmHg) 132.0 (14.7)
Asian 5706 (9.5) DBP (mmHg) 75.0 (9.6)
Black 2648 (4.4) Amputation 488 (0.8)
Mixed 552 (0.9) Peripheral neuropathy 3845 (6.4)
Other 557 (0.9) Retinopathy 21,408 (35.5)
IMD recorded 59,830 (99.2) Peripheral vascular disease 2191 (3.6)
IMD scorea 21.0 (16.3) Hypertension 35,657 (59.1)
Smoking status recorded 60,067 (99.6) Atrial ﬁbrillation 5302 (8.8)
Never 20,227 (33.5) Angina 4970 (8.2)
Current 7932 (13.1) Stroke 2605 (4.3)
Ex-smoker 31,908 (52.9) Myocardial infarction 2886 (4.8)
Alcohol use recorded 54,768 (90.8) Congestive cardiac failure 3427 (5.7)
None 18,469 (30.6) Transient ischaemic attack 1960 (3.2)
Within limits 12,489 (20.7) Coronary artery diseasec 5374 (8.9)
Excess 23,810 (39.5) Chronic kidney diseased 11,164 (18.5)
Duration of diabetes recorded 60,327 (100.0) Renal replacement therapy 335 (0.6)
\4 years 18,864 (31.3) Dementia 2218 (3.7)
4 B x\7 years 12,066 (20.0) Depression 7366 (12.2)
7 B x\10 years 10,994 (18.2) Rheumatoid arthritis 1074 (1.8)
C 10 years 18,403 (30.5) Chronic liver disease 3231 (5.4)
SD standard deviation, IMD index of multiple deprivation, BMI body mass index, SBP systolic blood pressure, DBP
diastolic blood pressure, LDL low-density lipoprotein, eGFR estimated glomerular ﬁltration rate
a A higher score equates to a higher level or deprivation, although the scale is nonlinear
b HbA1c value at the time of diagnosis
c A composite of myocardial infarction, revascularisation procedures, and acute cardiac syndrome
d Chronic kidney disease includes stages 3–5 only
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In Cox regression analyses (Table 4), factors
associated with improved medication persis-
tence were found to include older age, male
gender, white ethnicity (Fig. 1), HbA1c 42–-
60 mmol/mol, presence of hypertension, and
no previous glucose-lowering medication use.
Factors associated with non-persistence include
the presence of neuropathy, a history of
myocardial infarction, heart failure, dementia,
depression, and chronic liver disease. All medi-
cation classes had higher adjusted hazard ratios
for non-persistence than for metformin, except
for the SGLT2 inhibitors. Variables not associ-
ated with persistence (and therefore removed
from the model) were smoking status, body
mass index (BMI), previous amputations,
retinopathy, atrial fibrillation, angina, previous
stroke or transient ischaemic attack (TIA), and
use of renal replacement therapy.
Table 2 The number of people with type 2 diabetes
(n = 60,327) who were prescribed medication during the
follow-up period
Medication class Number of people
prescribed
medication in
class, n (%)
Number of
medication
persistence
events, n
Metformin 41,317 (68.5) 30,156
Sulfonylureas 20,819 (34.5) 11,347
DPP-4 inhibitors 9614 (15.9) 8125
Thiazolidinediones 6084 (10.1) 4308
SGLT2 inhibitors 1642 (2.7) 1439
Meglitinides 602 (1.0) 244
Alpha-glucosidase
inhibitors
370 (0.6) 109
The number of medication persistence events can include
several medications within the same class taken by a single
person where two new prescriptions were identiﬁed during
the follow-up period
Table 3 Median medication persistence duration and the number of people remaining persistent with medication at
6 months, 1 year, 2 years, and 5 years by medication class
Medication class Median
persistence
years (95% CI)
Persistence at
6 months
% (95% CI)
Persistence at
1 year
% (95% CI)
Persistence at
2 years
% (95% CI)
Persistence at
5 years
% (95% CI)
Metformin 3.04
(2.94–3.12)
80.5 (80.9–80.0) 70.1 (70.6–69.6) 58.0 (58.6–57.4) 39.6 (40.2–39.0)
Sulfonylureas 2.12
(2.03–2.23)
76.6 (77.4–75.8) 64.8 (65.7–63.9) 51.3 (52.3–50.3) 31.6 (32.7–30.6)
DPP-4 inhibitors 1.69
(1.62–1.78)
76.1 (77.0–75.1) 62.2 (63.3–61.0) 45.5 (46.8–44.2) 23.0 (24.5–21.5)
Thiazolidinediones 1.55
(1.48–1.64)
75.6 (76.8–74.2) 61.2 (62.7–59.8) 43.0 (44.5–41.5) 15.7 (16.8–14.5)
SGLT2 inhibitors NA 79.5 (81.7–76.9) 69.5 (72.5–66.2) 54.8 (60.8–48.2) NA
Meglitinides 0.81
(0.58–1.08)
58.4 (64.3–51.8) 45.1 (51.3–38.7) 28.8 (34.7–23.0) 7.5 (11.9–4.3)
Alpha-glucosidase
inhibitors
0.64
(0.27–0.85)
52.0 (61.0–42.0) 35.3 (44.6–26.2) 26.3 (35.4–18.0) 13.7 (22.2–7.2)
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Table 4 Results of Cox regression analysis for the hazard ratio (HR) of non-persistence with medication, adjusting for
patient characteristics and medication class
Characteristic n (%)* HR (95% CI) p value
Age
B 30 years 373 (0.7) 1.66 (1.46–1.87) \0.001
30–50 years 8912 (16.0) 1.00 [reference]
51–60 years 13,571 (24.4) 0.83 (0.80–0.86) \0.001
61–75 years 23,375 (41.9) 0.76 (0.73–0.78) \0.001
[75 years 9497 (17.0) 0.75 (0.71–0.78) \0.001
Male 32,162 (57.7) 0.93 (0.91–0.95) \0.001
Ethnicity
White 40,540 (72.7) 1.00 [reference]
Asian 4871 (8.7) 1.53 (1.47–1.59) \0.001
Black 2016 (3.6) 1.83 (1.73–1.93) \0.001
Mixed 453 (0.8) 1.29 (1.15–1.45) \0.001
Other 470 (0.8) 1.58 (1.41–1.77) \0.001
Not recorded 7378 (13.2) 0.99 (0.96–1.02) 0.598
IMD quintile
1 (most deprived) 11,228 (20.1) 1.00 [reference]
2 9669 (17.4) 1.05 (1.02–1.09) 0.004
3 9315 (16.7) 1.01 (0.97–1.05) 0.614
4 12,111 (21.7) 0.97 (0.94–1.01) 0.123
5 (least deprived) 13,041 (23.4) 0.93 (0.90–0.96) \0.001
Not recorded 364 (0.7) 1.06 (0.92–1.21) 0.429
Alcohol intake
None 17,697 (31.8) 1.00 [reference]
Within recommended limits 11,327 (20.3) 1.02 (0.99–1.05) 0.232
Over recommended limits 21,849 (39.2) 1.00 (0.97–1.03) 0.958
Alcoholic 1642 (2.9) 1.09 (1.02–1.16) 0.016
Not recorded 3213 (5.8) 1.13 (1.07–1.18) \0.001
HbA1c (mmol/mol)
x\42 1070 (1.9) 1.13 (1.04–1.22) 0.004
42 B x\50 5139 (9.2) 1.00 [reference]
50 B x\60 13,428 (24.1) 0.95 (0.92–1.00) 0.030
60 B x\70 13,922 (25.0) 0.99 (0.95–1.03) 0.696
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Table 4 continued
Characteristic n (%)* HR (95% CI) p value
70 B x\100 15,902 (28.5) 1.10 (1.06–1.15) \0.001
C 100 4103 (7.4) 1.16 (1.10–1.23) \0.001
Not measured 2164 (3.9) 1.16 (1.09–1.24) \0.001
Duration of diabetes (years)
1–3 24,922 (44.7) 1.00 [reference]
4–6 13,063 (23.4) 0.98 (0.95–1.01) 0.166
7–9 10,309 (18.5) 0.96 (0.93–0.99) 0.013
C 10 7434 (13.3) 0.95 (0.91–0.99) 0.012
Complications
Peripheral neuropathy 4604 (8.3) 1.08 (1.04–1.12) \0.001
Comorbidities
Hypertension 34,060 (61.1) 0.96 (0.93–0.98) \0.001
Myocardial infarction 2678 (4.8) 1.07 (1.02–1.12) 0.011
Congestive cardiac failure 3254 (5.8) 1.08 (1.03–1.13) 0.002
CKD stages 3–5 10,647 (19.1) 1.09 (1.06–1.12) \0.001
Dementia 1599 (2.9) 1.07 (1.01–1.14) 0.027
Depression 7286 (13.1) 1.08 (1.05–1.12) \0.001
Chronic liver disease 3492 (6.3) 1.12 (1.07–1.17) \0.001
Number of previous oral glucose-lowering medications
None 39,986 (71.8) 1.00 [reference]
One 10,156 (18.2) 1.06 (1.03–1.10) \0.001
Two 3731 (6.7) 1.13 (1.08–1.18) \0.001
Three or more 1855 (3.3) 1.13 (1.06–1.21) \0.001
Number of concurrent oral glucose-lowering medications
None 13,164 (23.6) 1.00 [reference]
One 20,686 (37.1) 1.08 (1.04–1.12) \0.001
Two or more 21,878 (39.3) 0.93 (0.90–0.97) \0.001
Medication class
Metformin 30,156 (54.1) 1.00 [reference]
Sulfonylureas 11,347 (20.4) 1.20 (1.16–1.24) \0.001
Thiazolidinediones 4308 (7.7) 1.71 (1.64–1.77) \0.001
DPP-4 inhibitors 109 (0.2) 1.43 (1.38–1.49) \0.001
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DISCUSSION
Medication persistence with glucose-lowering
agents differs considerably between classes;
persistence with metformin was significantly
longer than that with any other medication
class except for SGLT2 inhibitors (although only
a short duration of follow-up was available for
this new drug class). Only metformin, sulfony-
lureas, and SGLT2 inhibitors had more than
50% persistence at 2 years. Alpha-glucosidase
inhibitors have the highest rates of non-persis-
tence in clinical practice. Younger people and
people of non-white ethnicity had the lowest
medication persistence.
The effect size for influence on medication
persistence was largest for medication class.
This suggests that the class of medication used
is the major factor which influences the
duration of a selected treatment in type 2 dia-
betes. Whilst this finding may be unsurprising,
it has important implications. Careful selection
of second-line therapy after metformin, with a
preference for therapies which have longer
treatment persistence, may facilitate better
long-term diabetes control. However, medica-
tion persistence is not uniformly positive. For
instance, extended duration of sulphonylureas
may not be beneficial as the effects of treatment
wane over time when compared to those of an
insulin-independent therapy [42, 43]. Similarly,
reduced persistence in those with HbA1c less
than 42 mmol/mol suggests appropriate dis-
continuation in those at risk of hypoglycaemia.
Comparison with the Literature
We concurred with previous analyses that
demonstrated reduced medication adherence in
women [6, 30, 44, 45]. We found that a corre-
lation with reduced duration of mediation per-
sistence remained after adjusting for other
factors.
The identified differences in medication
persistence between people of different ethnic-
ities should be cause for concern. It has previ-
ously been reported that ethnic minorities show
reduced medication adherence [44, 46, 47], but
no previous study has been able to adjust for
socioeconomic status. The finding that these
differences are still substantial in a healthcare
system free at the point of delivery, and after
adjusting for socioeconomic status, is an
important finding. This is particularly so, given
that a number of the ethnic groups with shorter
medication persistences have higher preva-
lences of diabetes and diabetes-related
Table 4 continued
Characteristic n (%)* HR (95% CI) p value
SGLT2 inhibitors 1439 (2.6) 1.04 (0.93–1.17) 0.458
Meglitinides 244 (0.4) 2.25 (1.97–2.58) \0.001
Alpha-glucosidase inhibitors 8125 (14.6) 2.45 (1.98–3.02) \0.001
* n and percentage values reﬂect the number of prescriptions within the study cohort not the number of individuals
Number of medications included = 55,728. Model R2 = 0.061
Fig. 1 A Kaplan–Meier plot of medication persistence in
people by ethnicity group. Red line white, blue Asian,
yellow black. 95% conﬁdence intervals are shown by the
shaded areas
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complications [48]. These observed differences
merit further investigation. In particular, pos-
sible causes of this disparity should be
identified.
Our finding concurred with previous studies
which found that the presence of depression
and other comorbidities was associated with
reduced medication adherence [49–52]. How-
ever, we found that hypertension was associated
with slightly longer persistence. Our findings
also concurred with others which have
demonstrated reduced adherence in younger
people with type 2 diabetes [6, 30, 44, 45, 53].
We have extended these previous analyses to
demonstrate that the association with persis-
tence is non-linear; there is substantially
reduced medication persistence in those under
30 years old when compared to the other age
groups. This may represent lifestyle factors or be
due to early beta-cell failure and a misdiagnosed
autoimmune aetiology (with a need for early
escalation of therapy) to type 2 diabetes [54].
These factors which influence medication per-
sistence merit further investigation, and to this
end we have initiated a follow-on qualitative
analysis of factors influencing medication use in
people with type 2 diabetes [Integrated Research
Application System (IRAS) application number;
230092].
No direct comparison of medication persis-
tence across all groups of diabetes medications
has previously been performed [55]. Our data
suggest that medication class is the major
influencing factor in medication persistence.
Strengths and Limitations
The large population size, long duration of fol-
low-up and completeness of the patient record
are the main strengths of this analysis. In par-
ticular, the availability of a recognised measure
of socioeconomic status and of previous and
concurrent medication numbers add validity to
the conclusion that medication class is the
major influencing factor in medication
persistence.
Non-persistence is defined retrospectively,
with a non-persistence event only identified
90 days after the last medication prescription.
This may have artificially inflated the apparent
persistence for medications that have not been
available for a long time period, such as the
SGLT2 inhibitors. Re-evaluation of persistence
rates with these medications is needed as more
data become available. Our inclusion of drug
switching within a class as a non-persistence
event may mean our data shows lower persis-
tence rates than others that have not included
this. In the absence of a formal definition, we
have chosen this method to fit best with previ-
ous recommendations [34].
We were unable to adjust for some factors
which have been shown to be associated with
medication adherence or persistence, such as
proximity to pharmacy, continuity of care, and
level of trust in the healthcare provider [56–58].
However, it is unlikely that the inclusion of
these factors would substantially alter the asso-
ciations identified here. Factors underlying the
reasons for differences in non-persistence
between classes were not explored in this
analysis.
CONCLUSIONS
Important factors associated with reduced
medication persistence are female gender,
younger age, and non-white ethnicity. After
adjusting for these and other factors, medica-
tion persistence varies considerably across dif-
ferent medication classes and within
medication classes, with medication class being
the most important predictor of persistence.
Metformin was associated with significantly
longer persistence than all other medication
classes except for SGLT2 inhibitors. SGLT2
inhibitors also show early promise for good
persistence, although median persistence was
not reached by the end of the follow-up in this
study because only a short follow-up duration
for this class was available.
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